Skip to content

CERO THERAPEUTICS HOLDINGS, INC.: 10-Q/A filed 2024-11-20

What CERO THERAPEUTICS HOLDINGS, INC. reported in its quarterly report amendment filed 2024-11-20 (fiscal Q3 2024): 29 published measures, 93 facts as tagged in accession 0001213900-24-100303.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2024-11-20
Fiscal period
fiscal Q3 2024
Accession
0001213900-24-100303 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CERO THERAPEUTICS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-306,491,997USD
At 2023-12-315,126,302USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-3010,194,422USD
At 2023-12-315,082,653USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-3,702,425USD
At 2023-12-31-42,057,695USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-4,227,967USD92
2024-02-14 to 2024-09-30-8,404,104USD230
2024-01-01 to 2024-02-13-572,211USD44
2023-07-01 to 2023-09-30-1,349,347USD92
2023-01-01 to 2023-09-30-6,024,395USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-71,589,745USD
At 2023-12-31-43,089,821USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-3049,675,773shares92
2024-02-14 to 2024-09-3030,000,286shares230
2024-01-01 to 2024-02-139,068,899shares44
2023-07-01 to 2023-09-309,068,899shares92
2023-01-01 to 2023-09-309,058,608shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-3049,675,773shares92
2024-02-14 to 2024-09-3030,000,286shares230
2024-01-01 to 2024-02-139,068,899shares44
2023-07-01 to 2023-09-309,068,899shares92
2023-01-01 to 2023-09-309,058,608shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.09USD/shares92
2024-02-14 to 2024-09-30-0.28USD/shares230
2024-01-01 to 2024-02-13-0.06USD/shares44
2023-07-01 to 2023-09-30-0.15USD/shares92
2023-01-01 to 2023-09-30-0.67USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.09USD/shares92
2024-02-14 to 2024-09-30-0.28USD/shares230
2024-01-01 to 2024-02-13-0.06USD/shares44
2023-07-01 to 2023-09-30-0.15USD/shares92
2023-01-01 to 2023-09-30-0.67USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-09-30624,900USD
At 2023-12-31966,702USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-4,402,238USD92
2024-02-14 to 2024-09-30-13,205,412USD230
2024-01-01 to 2024-02-13-897,133USD44
2023-07-01 to 2023-09-30-1,535,571USD92
2023-01-01 to 2023-09-30-6,553,876USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-303,714,483USD
At 2023-12-311,970,035USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-309,422,897USD
At 2023-12-313,507,154USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-306,667,073USD
At 2023-12-311,671,745USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-304,402,238USD92
2024-02-14 to 2024-09-3013,205,412USD230
2024-01-01 to 2024-02-13897,133USD44
2023-07-01 to 2023-09-301,535,571USD92
2023-01-01 to 2023-09-306,553,876USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,774,210USD92
2024-02-14 to 2024-09-305,392,569USD230
2024-01-01 to 2024-02-13764,192USD44
2023-07-01 to 2023-09-301,277,558USD92
2023-01-01 to 2023-09-304,270,472USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-12-319,068,899shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-303,380,204USD
At 2023-12-311,601,255USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-3066,363,448USD
At 2023-12-311,031,219USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-09-301,652,614USD
At 2023-12-312,189,565USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-09-301,702,548USD
At 2023-12-312,344,591USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-09-301,929,691USD
At 2023-12-311,587,889USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-09-301,692,527USD
At 2023-12-31144,633USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-09-30334,279USD
At 2023-12-31368,780USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-302,628,028USD92
2024-02-14 to 2024-09-307,812,843USD230
2024-01-01 to 2024-02-13132,941USD44
2023-07-01 to 2023-09-30258,013USD92
2023-01-01 to 2023-09-302,283,404USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-07-01 to 2024-09-30113,855USD92
2024-02-14 to 2024-09-30304,446USD230
2024-01-01 to 2024-02-1337,356USD44
2023-07-01 to 2023-09-30115,388USD92
2023-01-01 to 2023-09-30346,164USD273

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-4,418USD92
2024-02-14 to 2024-09-3026,993USD230
2024-01-01 to 2024-02-13-4,805USD44
2023-07-01 to 2023-09-30-157USD92
2023-01-01 to 2023-09-30-118,251USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30174,271USD92
2024-02-14 to 2024-09-304,801,308USD230
2024-01-01 to 2024-02-13324,922USD44
2023-07-01 to 2023-09-30186,224USD92
2023-01-01 to 2023-09-30529,481USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,700,000USD92
2024-02-14 to 2024-09-304,300,000USD230

Inspect the source

Entity
CERO THERAPEUTICS HOLDINGS, INC. / CIK 0001870404
Captured
2026-09-19T11:21:59.403Z
SEC response SHA-256
8c8c2bd97bf9d18c6c5d6af2474c4302fa2e6a98d7edbc511d62e8f44742c0ac

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001870404.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))